Allison Inserro

Allison is Associate Editorial Director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®. She joined AJMC® in 2017. She produces and oversees written, video, and podcast content across several disease states and issues surrounding value-based care and health policy.

She has an MPA from New York University. You can connect with Allison on LinkedIn.

Articles by Allison Inserro

A federal judge in Texas ruled that the Affordable Care Act's individual coverage mandate is unconstitutional and that the rest of the law must also fall, likely setting up a fight in the Supreme Court and throwing into question the idea that consumers should have protection against discrimination by insurers for having pre-existing health conditions.

The CDC reported the number of drug overdose deaths per year increased 54% from 2011 to 2016, with the synthetic drug fentanyl involved in most overdoses in 2016, although actual numbers of all overdose deaths may be underreported. The report also showed how multiple drugs are typically involved in overdose deaths.

A large coalition of medical associations, patient advocacy groups, drug companies, and others sent a letter to Congress Monday asking that they intervene on a CMS plan to use an index based on drug prices in other countries to determine reimbursement for Part B therapies, saying it would have a negative effect on the elderly and people with disabilities.

CMS actuaries reported Thursday that overall national healthcare spending growth slowed for the second year in a row, due to slower spending growth in every area: hospital care, physician and clinical services, and retail prescription drugs. The slower pace also stemmed from the expanded coverage effects of the Affordable Care Act taking root in 2014 and 2015 and then falling off, as well as the decrease in usage of hepatitis C prescription drugs.

While a full repeal of the Affordable Care Act (ACA) in Congress failed last year, the Trump administration, in the courts and through regulation, has managed to get closer and closer to its goal as a matter of practicality. As health policy watchers wait for an impending decision to drop in Texas v Azar, the case about the constitutionality of the ACA, here is a look back at the healthcare actions taken during the first 2 years of the Trump administration.

With health policy increasingly transferring to the state level, what’s the most effective way for states to cover the majority of their population through affordable health insurance leveraging public funds? On a day when the Trump administration unveiled 4 ways states can request Section 1332 waivers, some of which are aimed at avoiding key parts of the Affordable Care Act (ACA), an advocacy organization released its own proposal to cover more of the uninsured and lower health insurance costs.

CMS Administrator Seema Verma announced consumers buying health insurance through the exchanges set up by the Affordable Care Act (ACA) would be allowed to have heath savings accounts, and the agency will allow states to set their own subsidies and decide what type of health plan is eligible for subsidies. In addition, waivers would be evaluated against the Hyde amendment.

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, and for COPD Awareness Month this November, The American Journal of Managed Care® conducted a Q&A with Jamie Sullivan, MPH, vice president of public policy and outcomes for The COPD Foundation, as well as Chief Medical Officer Byron M. Thomashow, MD. The COPD Foundation is a not-for-profit organization that works to improve the lives of patients with COPD.

The National Institutes of Health (NIH) said this week that care for chronic obstructive pulmonary disease (COPD) is expected to cost the United States $49 billion by 2020, as it recapped its research portfolio to mark World COPD Day 2018.

A pharmaceutical company proactively reached out to the Office of the Inspector General (OIG) of HHS to find out if giving a costly drug for a rare condition—free of charge, in the hope of eventually getting the drug covered by payors—to hospitals would violate federal kickback law, and was told it probably would.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo